Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. [electronic resource]
Producer: 20090820Description: 3642-9 p. digitalISSN:- 1527-7755
- Analysis of Variance
- Benzamides
- Blast Crisis -- genetics
- Cohort Studies
- DNA Mutational Analysis
- Drug Resistance, Neoplasm -- drug effects
- Female
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic -- drug effects
- Genes, abl
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Mutation -- drug effects
- Pharmacogenetics
- Piperazines -- administration & dosage
- Probability
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Retrospective Studies
- Risk Assessment
- Severity of Illness Index
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.